Today, Solve joined #MEAction, Bateman Horne Center, Simmaron Research, Open Medicine Foundation, and other organizations in a sign-on letter urging the National Institutes of Health (NIH) leadership to include subgroup tracking and analysis for ME/CFS (using IOM criteria), POTS and other forms of dysautonomia, and MCAS in its RECOVER-TLC clinical trials.
Solve President and CEO Emily Taylor stated, “Solve joined this call to NIH leadership because people with ME/CFS, Long Covid, and related illnesses like POTS and MCAS deserve research that truly reflects their realities. By ensuring clinical trials account for the differences among patients, we can accelerate discoveries that lead to real treatments and improved care. This is a moment of great responsibility, and we are committed to making sure science rises to meet the needs of millions still waiting for answers.”
Read the letter here.